JP Morgan Chase’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-524,184
| Closed | -$787K | – | 7513 |
|
|
2023
Q1 | $787K | Hold |
524,184
| – | – | ﹤0.01% | 4204 |
|
|
2022
Q4 | $524K | Sell |
524,184
-1,564
| -0.3% | -$2.11K | ﹤0.01% | 4476 |
|
|
2022
Q3 | $947K | Sell |
525,748
-174,142
| -25% | -$505K | ﹤0.01% | 4044 |
|
|
2022
Q2 | $2.03M | Sell |
699,890
-13,723
| -2% | -$33.9K | ﹤0.01% | 3535 |
|
|
2022
Q1 | $1.97M | Sell |
713,613
-217,222
| -23% | -$683K | ﹤0.01% | 3760 |
|
|
2021
Q4 | $4.34M | Sell |
930,835
-99,525
| -10% | -$622K | ﹤0.01% | 3184 |
|
|
2021
Q3 | $8.77M | Buy |
1,030,360
+370,949
| +56% | +$5.24M | ﹤0.01% | 2502 |
|
|
2021
Q2 | $10.8M | Buy |
659,411
+4,597
| +0.7% | +$92.9K | ﹤0.01% | 2364 |
|
|
2021
Q1 | $14.5M | Buy |
654,814
+194,667
| +42% | +$5.31M | ﹤0.01% | 2020 |
|
|
2020
Q4 | $14.2M | Buy |
460,147
+196,273
| +74% | +$4.96M | ﹤0.01% | 1906 |
|
|
2020
Q3 | $5.11M | Buy |
263,874
+18,315
| +7% | +$322K | ﹤0.01% | 2546 |
|
|
2020
Q2 | $3.77M | Buy |
245,559
+20,058
| +9% | +$231K | ﹤0.01% | 2668 |
|
|
2020
Q1 | $1.75M | Buy |
225,501
+18,197
| +9% | +$223K | ﹤0.01% | 3067 |
|
|
2019
Q4 | $2.96M | Buy |
207,304
+5,288
| +3% | +$81.8K | ﹤0.01% | 3095 |
|
|
2019
Q3 | $3.04M | Buy |
202,016
+9,679
| +5% | +$151K | ﹤0.01% | 3118 |
|
|
2019
Q2 | $2.79M | Sell |
192,337
-6,384
| -3% | -$102K | ﹤0.01% | 3144 |
|
|
2019
Q1 | $3.46M | Buy |
+198,721
| New | +$3.52M | ﹤0.01% | 2896 |
|
JP Morgan Chase's TCRR Position: Q2 2023 in Review
JP Morgan Chase sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 524,184 shares — an estimated $787K sold.
JP Morgan Chase first reported a position in TCRR in Q1 2019 and held it in 17 quarters. The position peaked at $14.5M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- JP Morgan Chase reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- JP Morgan Chase sold 524,184 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $787K.
- JP Morgan Chase first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 17 quarters.
- JP Morgan Chase's TCR2 Therapeutics Inc. Common Stock position peaked at $14.5M in Q1 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.